Johnson & Johnson (JNJ)

This particular sector may suit cautious and aggressive investors.

Wall Street analysts expect market-beating returns from healthcare and communication services stocks over the next year.

AbbVie's shareholders can sleep easy.

The Vanguard Health Care ETF (VHT) and the iShares Global Healthcare ETF (IXJ) both target health care stocks, but they are tailored to different investor needs. One emphasizes broad, low-cost U.S. exposure, while the other adds global reach in a sector shaped by drug pricing, patent cycles, regulation, and medical innovation.

Legend Biotech (NASDAQ:LEGN) used an investor and analyst event to highlight long-term data and physician perspectives supporting broader use of CARVYKTI, its BCMA-directed CAR T-cell therapy for multiple myeloma developed, manufactured and co-promoted with Johnson & Johnson. Chief Executive Of

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

High energy prices have investors worried about a recession; these businesses should survive the hit just fine.

Walmart is facing short-term pressures that are leading investors to miss the long-term opportunity.

When choosing dividend ETFs, diversification is a top priority.

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 15th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.

Don't be too quick to give up on the industry.

Johnson & Johnson sells products that are necessities, not just nice-to-haves.

O-I Glass manufactures glass containers for food and beverage makers across the Americas, Europe, and Asia Pacific.

The healthcare sector outperformed the rest of the market over the past week.

ExxonMobil, Johnson & Johnson, and Coca-Cola are safe stocks to buy and forget.

When it comes to reliable dividend payouts, these three companies keep rewarding their long-term shareholders.

It has plenty of other qualities investors should take note of.

Get greedy for these blue chip dividend stocks when Wall Street gets fearful.

BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (“BBB”), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer’s disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine’s most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct, targeted access to the central nervous system (“CNS”). Oncotelic has developed a proprietary intranasal nose-to-brain (“N2B”) system capable of rapidly shuttling therapeutics to the brain, a signal of growing industry consensus that delivery innovation, not merely drug discovery, will drive the next wave of breakthroughs in CNS medicine. Oncotelic joins a group of leading biopharma companies working in the biopharmaceutical and advanced therapeutics space, including Amgen Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV) and…